Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.

[1]  G. Romano,et al.  Selective inhibition of PED protein expression sensitizes B‐cell chronic lymphocytic leukaemia cells to TRAIL‐induced apoptosis , 2007, International journal of cancer.

[2]  Jihong Chen,et al.  Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B , 2006, Molecular Cancer.

[3]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[4]  Satoshi Inoue,et al.  Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. , 2006, Cancer research.

[5]  B. Hylander,et al.  Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL , 2006, Molecular Cancer Therapeutics.

[6]  D. Schrump,et al.  Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. , 2006, Neoplasia.

[7]  C. Cho,et al.  Hydroxychloroquine potentiates Fas‐mediated apoptosis of rheumatoid synoviocytes , 2006, Clinical and experimental immunology.

[8]  Tao Liu,et al.  Histone deacetylase inhibitors: multifunctional anticancer agents. , 2006, Cancer treatment reviews.

[9]  S. O'brien,et al.  Initial therapy for patients with chronic lymphocytic leukemia. , 2006, Seminars in oncology.

[10]  J. Vávrová,et al.  Effect of valproic acid and antiapoptotic cytokines on differentiation and apoptosis induction of human leukemia cells. , 2006, General physiology and biophysics.

[11]  Afshin Samali,et al.  TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt , 2006, British Journal of Cancer.

[12]  E. Rowinsky.  Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Fanin,et al.  Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B‐CLL) cells , 2005, Journal of cellular physiology.

[14]  A. Burny,et al.  Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Cohen,et al.  Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1 , 2005, Cell Death and Differentiation.

[16]  R. Blaheta,et al.  Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies , 2005, Medicinal research reviews.

[17]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Rotoli,et al.  Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis. , 2005, Immunology letters.

[19]  S. Inoue,et al.  Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies , 2004, Cell Death and Differentiation.

[20]  C. Croce,et al.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  O. Legrand,et al.  Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1 , 2004, Leukemia.

[22]  M. Tallman,et al.  Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. , 2004, Leukemia research.

[23]  M. Grever,et al.  The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells , 2004, Leukemia.

[24]  P. Atadja,et al.  Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells , 2004, Cancer Research.

[25]  R. Kuefer,et al.  Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer , 2004, British Journal of Cancer.

[26]  E. Taubøll,et al.  Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7 , 2004, Molecular and Cellular Endocrinology.

[27]  Adrian Wiestner,et al.  ZAP-70 expression and prognosis in chronic lymphocytic leukaemia , 2004, The Lancet.

[28]  Jian Kang,et al.  Chemical sensitization and regulation of TRAIL‐induced apoptosis in a panel of B‐lymphocytic leukaemia cell lines , 2003, British journal of haematology.

[29]  M. Andreeff,et al.  Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  M. Grever,et al.  Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. , 2003, Blood.

[31]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[32]  G. Cohen,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia , 2002, Oncogene.

[33]  K. Sano,et al.  Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. , 2002, Leukemia research.

[34]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  J. Byrd,et al.  The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. , 2002, Blood.

[36]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[37]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[38]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.

[39]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[40]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[41]  Xiaodong Wang,et al.  Nucleotide Requirements for the in Vitro Activation of the Apoptosis Protein-activating Factor-1-mediated Caspase Pathway* , 2000, The Journal of Biological Chemistry.

[42]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[43]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[44]  L. Lagneaux,et al.  Chronic Lymphocytic Leukemic B Cells But Not Normal B Cells Are Rescued From Apoptosis by Contact With Normal Bone Marrow Stromal Cells , 1998 .

[45]  K. Struhl.  Histone acetylation and transcriptional regulatory mechanisms. , 1998, Genes & development.

[46]  J. Cinatl,et al.  Sodium valproate inhibits in vivo growth of human neuroblastoma cells. , 1997, Anti-cancer drugs.

[47]  D. P. Bentley,et al.  Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. , 1997, British Journal of Cancer.

[48]  D. Oscier,et al.  Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. , 1997, Blood.

[49]  R. Levy,et al.  Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. , 1992, Molecular immunology.

[50]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[51]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[52]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[53]  A. Teufel,et al.  Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. , 2006, Oncology reports.

[54]  A. Zelenetz,et al.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  C. Steidl,et al.  The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia , 2006, Cancer.

[56]  K. Watanabe,et al.  Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP , 2005, Cell Death and Differentiation.

[57]  P. Atadja,et al.  Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. , 2004, Haematologica.

[58]  J. Byrd,et al.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). , 2003, Blood.

[59]  Vigushin Dm,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002 .